{"acquisitions":[],"changes":[],"country":"US","description":"Clinical-stage biotech building glyco-immune therapeutics using its HALOS Siglec-targeting platform to modulate the innate immune system. Targets patients with geographic atrophy, retinal disease and chronic inflammatory conditions. Lead asset AVD-104 is in Phase 2b for geographic atrophy with about 300 patients enrolled across three arms.","domain":"avicedatx.com","employees":null,"founded":2018,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":52.197585,"lng":0.139154,"location":"Cambridge","multiples":[],"name":"Aviceda Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":208000000,"connectionsAmong":[],"currency":"USD","date":"2025-01-08","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"avicedatx-com-2025-01-08-series-c","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"series-c","url":null}],"slug":"avicedatx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"avicedatx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://avicedatx.com"},{"fact":"description","publisher":"avicedatx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://avicedatx.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":300000000,"traction":[],"updatedAt":"2026-05-07","valuations":[]}